In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Biogenics Ltd.

www.vblrx.com

Latest From Vascular Biogenics Ltd.

BMS’s Opdivo Misses Again In Glioblastoma Phase III Trial

A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.

Clinical Trials ImmunoOncology

Phase III Miss In Glioblastoma Burdens VBL's Ovarian Cancer Trial

It's bad news for Israel's VBL as the company's lead gene-based biologic has failed in a critical Phase III trial in brain cancer – the pressure is on now for success with this drug candidate in ovarian cancer.

Clinical Trials Research and Development Strategies

Eight Clinical Trial Read-Outs To Look Out For In Early 2018

The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.

Clinical Trials Research & Development

Deals Shaping The Medical Industry, December 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Inflammation
  • Renal System
  • Alias(es)
  • VBL Therapeutics
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Vascular Biogenics Ltd.
  • Senior Management
  • Dror Harats, MD, CEO
    Amos Ron, CFO
    Erez Feige, PhD, VP, Bus. Operations
    Yael Cohen, MD, VP, Clin. Dev.
  • Contact Info
  • Vascular Biogenics Ltd.
    Phone: (972) 8-9935000
    HaSatat 8 St.
    Modi’in, 7178106
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register